Assembly Biosciences…plans to host a webcast on Tuesday, July 26, 2022 from 1:30-2:30 pm PT/4:30-5:30 pm ET to introduce its new research program advancing a novel, small molecule interferon-alpha receptor (IFNAR) agonist designed to selectively activate the interferon-alpha pathway within the liver and offer the convenience of oral dosing.
As far as I know, no other HBV company is pursing this approach. I wonder why the webcast is scheduled for five weeks from now rather than sooner.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.